Vorster Luna, Kirk Susan E, Muscal Eyal, Despotovic Jenny M, Cohen Clay T, Sartain Sarah E
Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Pediatr Blood Cancer. 2022 Jun;69(6):e29681. doi: 10.1002/pbc.29681. Epub 2022 Apr 4.
The mRNA COVID-19 vaccine and COVID-19 infection caused by the SARS-CoV-2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). There is not yet literature that discusses TTP induced by COVID-19 vaccination or infection in pediatric or adolescent patients. We describe three adolescents presenting with TTP (both de novo and relapsed disease) following administration of the Pfizer COVID-19 vaccine or after COVID-19 infection. Our observations demonstrate that the Pfizer-BioNTech mRNA vaccine and COVID-19 infection can act as triggers for the development/relapse of both congenital and acquired TTP.
信使核糖核酸（mRNA）新冠疫苗以及由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒引起的新冠病毒感染可能是血栓性血小板减少性紫癜（TTP）发生的免疫触发因素。目前尚无文献讨论儿童或青少年患者因接种新冠疫苗或感染新冠病毒而诱发的TTP。我们描述了3例青少年在接种辉瑞新冠疫苗后或感染新冠病毒后出现TTP（包括初发和复发疾病）的情况。我们的观察结果表明，辉瑞-生物科技公司的mRNA疫苗和新冠病毒感染可作为先天性和获得性TTP发生/复发的触发因素。
